<DOC>
	<DOCNO>NCT00118612</DOCNO>
	<brief_summary>Allergen-specific immunotherapy ( SIT ) , administration gradually increase quantity allergen extract allergic patient , curative approach directly treat underlie allergic disease . Tree MATA MPL develop provide pre-seasonal specific immunotherapy patient allergy tree pollen ( hay fever ) . The purpose double-blind Phase IIb study ass tolerability immunogenicity different dos Tree MATA MPL volunteer allergic birch , hazel alder pollen .</brief_summary>
	<brief_title>Different Doses Tyrosine Adsorbed Tree Pollen Allergoid With Monophosphoryl Lipid A ( MPL ) Patients Sensitized Tree Pollen</brief_title>
	<detailed_description />
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Hypersensitivity , Immediate</mesh_term>
	<mesh_term>Monophosphoryl lipid A</mesh_term>
	<criteria>Patients must positive skin prick test birch hazel alder allergen . Positive skin prick test positive histamine control Negative skin prick test negative control Specific IgE birch document radioallergosorbent equivalent test class ≥ 2 History least 1 season moderate severe seasonal rhinoconjunctivitis due IgE mediate allergy pollen birch , hazel , alder Patients must score disease severity questionnaire moderate severe . Males nonpregnant , nonlactating female Patients normally active otherwise judge good health Patients must willing able attend require study visit . Patients must able follow instruction . Patients must willing able give write informed consent must provide consent . Acute subacute atopic dermatitis and/or urticaria factitia and/or urticaria due physical chemical influence and/or chronic dermatitis Moderate severe asthma Visual inspection forearm indicate potential problem conduct interpretation skin prick test ; forearm must available test . History presence diabetes , cancer clinically significant cardiac , metabolic , renal , hematologic disease disorder Recent clinically significant history hepatic , gastrointestinal , dermatologic , venereal , neurologic psychiatric disease disorder Any clinically significant abnormal laboratory value Visit 1 Perennial allergen : clinically relevant sensitivity house dust mite , mold , epithelium Patient clinically relevant sensitivity follow summer/autumn season flower plant : plantain , orache , nettle , mugwort , Parietaria judaica , Bermuda grass , ragweed . Secondary alteration affect organ History autoimmune disease and/or rheumatoid disease Patient take ßblockers indication include eye drop Patient allow receive adrenalin Patients tyrosine metabolism disturb Presence disease pathogenesis interfere immune response patient receive medication could influence result study Acute significant chronic infection History anaphylaxis Documented history angioedema Hypersensitivity excipients study medication Previous current immunotherapy comparable tree allergen extract Currently use antiallergy medication drug antihistaminic activity Patients currently participate clinical trial expose study medication within last 30 day Patients communicate reliably Investigator likely cooperate requirement study Patient pregnant planning pregnancy and/or lactate Patient receive treatment preparation contain MPL past 12 month Concurrent use prohibit medication ( ) , list study protocol , inadequate washout medication Any systemic disorder could interfere evaluation study medication ( ) Clinical history drug alcohol abuse , Investigator 's discretion , would interfere patient 's participation study Study site staff immediate relative study site staff individual would access clinical study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Allergy</keyword>
	<keyword>Specific Immunotherapy</keyword>
	<keyword>Allergy Vaccination</keyword>
	<keyword>Allergenicity</keyword>
</DOC>